Mylan shareholders today did not unseat the drug maker’s board of directors, despite calls for an ouster over the EpiPen pricing scandals and remarkably large executive salaries.

In a vote during an annual meeting in Amsterdam, shareholders approved all incumbent nominees, including Chief Executive Heather Bresch, President Rajiv Malik, and Chairman Robert Coury, who earned a nearly $100 million salary last year amid intense backlash over EpiPen price hikes. The majority of shareholders did, however, reject such executive compensation plans—in a nonbinding vote.

In recent weeks, a group of shareholders had campaigned to overthrow the board for what it called “significant reputational and financial harm” and “new lows in corporate stewardship.” The disgruntled shareholders were backed by an influential advisory firm, the Institutional Shareholder Services (ISS), which agreed that the EpiPen price increases and eye-popping executive salaries caused “significant destruction in shareholder value” and “long-term reputational damage.”

As Ars has noted before, Mylan’s governance rules make unseating the board difficult, requiring a two-thirds vote. Mylan has not released the breakdown of today’s vote, which is not sitting well with some shareholders.

In a statement e-mailed to Ars, New York City Comptroller Scott Stringer, who oversees New York City pensions that own more than 1.1 million shares of Mylan and led the campaign against the board, said:

Mylan’s silence speaks volumes. By failing to disclose the voting results during today’s shareowner meeting, Mylan’s board telegraphed that directors faced strong opposition. With its costly record of oversight failures and public relations debacles, this hardly comes as a surprise. This company massively hiked prices on life-saving drugs, allegedly overcharged the government for its products, and allowed excessive executive pay to go unchecked—all ultimately fundamental failures of board oversight. It’s not just investors who were harmed as a result—everyday consumers and American taxpayers also suffered.

A spokesperson for Mylan would not reveal the vote breakdown to Ars but said that the company will include the information in Securities and Exchange Commission filings in the next few days, which it has done in the past.

For its part, Mylan released a statement saying:

At Mylan’s June 22, 2017 annual general meeting, all directors nominated by Mylan’s Board of Directors were duly and validly elected. We appreciate our shareholders’ continuing support of the Mylan Board, which has overseen the development of a differentiated, clear, and consistent long-term strategy that has created sustained long-term growth and value for shareholders, while also serving the interests of other stakeholders. We look forward to continued shareholder engagement going forward.

Mylan’s statement went on to note that shareholders voted down the company’s compensation plans. “The Compensation Committee and Board of Directors will carefully consider these results, as well as future shareholder input, as we continue our investor outreach and in designing our compensation programs going forward.”

However, analysts say the vote is unlikely to have any effect. Speaking to Bloomberg Markets, Ronny Gal, an analyst with Sanford C. Bernstein & Co., said: “There’s no way for this to be enforced.” He noted that, when shareholders have pushed back on salaries in the past, “Mylan’s position was that they need to educate shareholders more on the drivers of why they compensate management the way they do. I would be surprised if they pursue a different path here.”